Transposon mutagenesis in Mycobacterium kansasii links a small RNA gene to colony morphology and biofilm formation and identifies 9,885 intragenic insertions that do not compromise colony outgrowth

In this study, we validated the functionality of a powerful Tn mutagenesis tool inMk and used this tool in conjunction with a forward genetic screen to establish a previously unrecognized role of a conserved mycobacterial small RNA gene of unknown function in colony morphology features and biofilm formation. We also combined Tn mutagenesis with next ‐generation sequencing to identify 12,071 Tn insertions that do not compromise viability in vitro. Finally, we demonstrated the susceptibility of theGalleria mellonella larva toMk, setting the stage for further exploration of this simple and economical infection model system to the study of this pathogen.
Source: MicrobiologyOpen - Category: Microbiology Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

P. Rathi et al.
Source: Emerging Infectious Diseases Journal - Category: Infectious Diseases Source Type: research
CONCLUSION: In the realm of development of more potent, effective, safer and less toxic antituberculosis agents; our current study would definitely help the medicinal chemists to develop potent analogues containing hydrazine motifs in them. PMID: 32209038 [PubMed - as supplied by publisher]
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research
Analytical ChemistryDOI: 10.1021/acs.analchem.9b05853
Source: Analytical Chemistry - Category: Chemistry Authors: Source Type: research
Publication date: Available online 19 March 2020Source: Journal of Global Antimicrobial ResistanceAuthor(s): Nilma Hirani, Ameeta Joshi, Siddharth Anand, Abhay Chowdhary, Karthik Ganesan, Meenal Agarwal, Nikhil Phadke
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Conclusions: Replacing an injectable-containing SCR with a bedaquiline-containing SCR is cost-effective, offering a cost-saving alternative with improved patient outcomes for MDR-TB. PMID: 32186925 [PubMed - as supplied by publisher]
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a standardised regimen of 9–12 months (the "shorter regimen") and individualised regimens of ≥20 months ("longer regimens"). We collected individual patient data from observational studies identified through systematic reviews and a public call for data. We included patients meeting WHO eligibility criteria for the shorter regimen: not previously treated with second-line drugs, and with fluoroquinolone- and...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections and tuberculosis Original Articles: Tuberculosis Source Type: research
This report evaluated global progress toward these targets based on data reported by WHO (1). Annual TB data routinely reported to WHO by 194 member states were used to estimate TB incidence and mortality overall and among persons with HIV infection, TB-preventive treatment (TPT) initiation, and drug-resistant TB for 2018 (1). In 2018, an estimated 10 million persons had incident TB, and 1.5 million TB-related deaths occurred, representing 2% and 5% declines from 2017, respectively. The number of persons with both incident and prevalent TB remained highest in the WHO South-East Asia and African regions. Decreases in the Eu...
Source: MMWR Morb Mortal Wkl... - Category: Epidemiology Authors: Tags: MMWR Morb Mortal Wkly Rep Source Type: research
With three new and three recently repurposed drugs, treatment of multidrug-resistant tuberculosis (MDR-TB) is more hopeful today than at any time since it emerged in the 1980s and 1990s [1–3]. This optimism contrasts starkly with dismal global treatment success rates of 48–56% as reported by the World Health Organization (WHO) in its annual Global Tuberculosis Reports from 2014 to 2019 [4, 5].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections and tuberculosis Editorials Source Type: research
AbstractA simple and environment friendly one-pot synthesis of ethyl 3,5-dicyano-6-oxo-2,4-diarylpiperidine-3-carboxylate derivatives from aryl aldehydes, ethyl cyanoacetate, and ammonium acetate was developed in aqueous medium without using a catalyst. The significant features of this method are easy, inexpensive experimental procedures with short reaction time and high yield. The use of water as the solvent without catalyst makes the reaction meritorious and further fulfilled green chemistry protocols. The compounds were screened for antibacterial activity against Gram-positive bacteria (Staphylococcus aureus 25923) and ...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Publication date: Available online 17 March 2020Source: The Lancet Respiratory MedicineAuthor(s): Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei, Linda Barkane, Andrea Benedetti, Sarah K Brode, James C M Brust, Jonathon R Campbell, Vicky Wai Lai Chang, Dennis Falzon, Lorenzo Guglielmetti, Petros Isaakidis, Russell R Kempker, Maia Kipiani, Liga Kuksa, Christoph Lange, Rafael Laniado-Laborín, Payam Nahid, Denise Rodrigues, Rupak Singla
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
More News: Biology | Genetics | Microbiology | Multidrug Resistance | Study | Tuberculosis